Breaking News, Promotions & Moves

ERS Genomics Appoints John E. Milad CEO

John brings more than 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ERS Genomics Ltd., a CRISPR licensing company, has appointed John E. Milad as CEO, effective immediately. John brings more than 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors.   As CEO of Quanta Dialysis Technologies for nearly a decade, John led the development and commercial launch of an award-winning portable haemodialysis system designed to transform the delivery of kidney care to patients...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters